Identification
- Summary
Sodium phosphate, dibasic is an osmotic laxative used to cleanse the colon before a colonoscopy.
- Brand Names
- Bss Ophthalmic Solution, Fleet Mineral Oil, Glycerolyte 57, Isolyte S pH 7.4, K-phos Neutral, Osmoprep, Pedia-lax Liquid, Phoxillum, Tis-U-sol
- Generic Name
- Sodium phosphate, dibasic
- DrugBank Accession Number
- DB14502
- Background
Not Available
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Sodium phosphate, dibasic (DB14502)
- Weight
- Average: 141.9588
Monoisotopic: 141.940784382 - Chemical Formula
- HNa2O4P
- Synonyms
- Dibasic sodium phosphate anhydrous
- Dibasic sodium phosphate, anhydrous
- Disodium acid phosphate
- Disodium hydrogen monophosphate
- Disodium hydrogen phosphate
- Disodium hydrogen phosphate, anhydrous
- disodium hydrogenphosphate
- Disodium phosphate
- Phosphoric acid, disodium salt, anhydrous
- Phosphoric acid, sodium salt (1:2)
- Sodium phosphate dibasic
- Sodium phosphate, dibasic
- Sodium phosphate, dibasic (anhydrous)
- Sodium phosphate, dibasic anhydrous
- Sodium phosphate, dibasic, anhydrous
- Sodium phosphate,dibasic,anhydrous
- External IDs
- E-339(II)
- Fema no. 2398
- INS NO.339(II)
- INS-339(II)
Pharmacology
- Indication
Used to treat constipation or to clean the bowel before a colonoscopy Label.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Associated Therapies
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Sodium phosphate inceases fecal water content to increase mobility through the large intestine 1.
- Mechanism of action
Sodium phosphate is thought to work by increasing the amount of solute present in the intestinal lumen thereby creating an osmotic gradient which draws water into the lumen 1.
- Absorption
Tmax for phosphate absorption with orally administered liquid sodium phosphate is 1-3h 3.
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Intamuscular LD50 of 250mg/kg and oral LD50 of 8290 mg/kg reported in rats 7. Phosphate toxicity is likely due to the disturbance of other electrolytes when phosphate levels are high, producing symptoms including tetany, dehydration, hypotension, tachycardia, hyperpyrexia, cardiac arrest and coma 4. Risk of raising phosphate levels through use of sodium phosphate appears to be higher in smaller patients 3.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAcetazolamide The risk or severity of dehydration can be increased when Acetazolamide is combined with Sodium phosphate, dibasic. Aclidinium The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aclidinium. Alfentanil The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Alfentanil. Alloin The risk or severity of adverse effects can be increased when Sodium phosphate, dibasic is combined with Alloin. Almasilate The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Almasilate. Aluminium phosphate The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminium phosphate. Aluminum hydroxide The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Aluminum hydroxide. Amantadine The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amantadine. Amiloride The risk or severity of dehydration can be increased when Amiloride is combined with Sodium phosphate, dibasic. Amiodarone The therapeutic efficacy of Sodium phosphate, dibasic can be decreased when used in combination with Amiodarone. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Take with a full glass of water.
- Take with food.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Sodium phosphate, dibasic dihydrate 94255I6E2T 10028-24-7 KDQPSPMLNJTZAL-UHFFFAOYSA-L Sodium phosphate, dibasic dodecahydrate E1W4N241FO 10039-32-4 DGLRDKLJZLEJCY-UHFFFAOYSA-L Sodium phosphate, dibasic, heptahydrate 70WT22SF4B 7782-85-6 PYLIXCKOHOHGKQ-UHFFFAOYSA-L Sodium phosphate, dibasic, monohydrate BWZ7K44R51 118830-14-1 LVXHNCUCBXIIPE-UHFFFAOYSA-L - Active Moieties
Name Kind UNII CAS InChI Key Sodium cation ionic LYR4M0NH37 17341-25-2 FKNQFGJONOIPTF-UHFFFAOYSA-N Phosphate ion ionic NK08V8K8HR 14265-44-2 NBIIXXVUZAFLBC-UHFFFAOYSA-K - Product Images
- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aminoplasmal B. Braun 10%E Solution for Intravenous Infusion Sodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Alanine (10.5 g/1000ml) + Arginine (11.5 g/1000ml) + Aspartic acid (5.6 g/1000ml) + Glutamic acid (7.2 g/1000ml) + Glycine (12 g/1000ml) + Histidine (3 g/1000ml) + Isoleucine (5 g/1000ml) + Leucine (8.9 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.4 g/1000ml) + Phenylalanine (4.7 g/1000ml) + Potassium acetate (2.453 g/1000ml) + Proline (5.5 g/1000ml) + Serine (2.3 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.36 g/1000ml) + Threonine (4.2 g/1000ml) + Tryptophan (1.6 g/1000ml) + Tyrosine (0.4 g/1000ml) + Valine (6.2 g/1000ml) Injection, solution Intravenous B.BRAUN MEDICAL INDUSTRIES SDN BHD 2020-09-08 Not applicable Malaysia 
AMINOPLASMAL B.BRAUN 10% E SOLUTION FOR INFUSION Sodium phosphate, dibasic dodecahydrate (3.581 g/1000ml) + Alanine (10.50 g/1000ml) + Arginine (11.50 g/1000ml) + Aspartic acid (5.60 g/1000ml) + Glutamic acid (7.20 g/1000ml) + Glycine (12.00 g/1000ml) + Histidine (3.00 g/1000ml) + Isoleucine (5.00 g/1000ml) + Leucine (8.90 g/1000ml) + Lysine hydrochloride (8.56 g/1000ml) + Magnesium chloride hexahydrate (0.508 g/1000ml) + Methionine (4.40 g/1000ml) + Phenylalanine (4.70 g/1000ml) + Potassium acetate (2.453 g/1000ml) + Proline (5.50 g/1000ml) + Serine (2.30 g/1000ml) + Sodium acetate trihydrate (2.858 g/1000ml) + Sodium hydroxide (0.360 g/1000ml) + Threonine (4.20 g/1000ml) + Tryptophan (1.60 g/1000ml) + Tyrosine (0.40 g/1000ml) + Valine (6.20 g/1000ml) Solution Intravenous B. BRAUN SINGAPORE PTE LTD 2018-01-23 Not applicable Singapore AMINOPLASMAL® 10% E Sodium phosphate, dibasic dodecahydrate (3.581 g) + Alanine (10.5 g) + Arginine (11.5 g) + Aspartic acid (5.6 g) + Glutamic acid (7.2 g) + Glycine (12 g) + Histidine (3 g) + Isoleucine (5 g) + Leucine (8.9 g) + Lysine hydrochloride (8.56 g) + Magnesium chloride hexahydrate (0.508 g) + Phenylalanine (4.7 g) + Potassium acetate (2.453 g) + Proline (5.5 g) + Racemethionine (4.4 g) + Serine (2.3 g) + Sodium acetate trihydrate (2.858 g) + Sodium hydroxide (0.36 g) + Threonine (4.2 g) + Tryptophan (1.6 g) + Tyrosine (0.4 g) + Valine (6.2 g) Solution Intravenous B. BRAUN MEDICAL S.A. 2015-07-27 Not applicable Colombia 
Aminosyn II 7% M In 10% Dextrose(dual Chamber) Sodium phosphate, dibasic (49 mg / 100 mL) + Alanine (348 mg / 100 mL) + Arginine (356 mg / 100 mL) + Aspartic acid (245 mg / 100 mL) + Dextrose, unspecified form (5 g / 100 mL) + Glutamic acid (258 mg / 100 mL) + Glycine (175 mg / 100 mL) + Histidine (105 mg / 100 mL) + Isoleucine (231 mg / 100 mL) + Leucine (350 mg / 100 mL) + Lysine acetate (368 mg / 100 mL) + Magnesium chloride (30 mg / 100 mL) + Methionine (60 mg / 100 mL) + N-acetyltyrosine (94 mg / 100 mL) + Phenylalanine (104 mg / 100 mL) + Potassium chloride (97 mg / 100 mL) + Proline (252 mg / 100 mL) + Serine (186 mg / 100 mL) + Sodium chloride (120 mg / 100 mL) + Threonine (140 mg / 100 mL) + Tryptophan (70 mg / 100 mL) + Valine (175 mg / 100 mL) Solution Intravenous Hospira Healthcare Ulc 1987-12-31 2012-08-03 Canada 
Aminosyn II 8.5% M In 20% Dextrose (dual Chamber) Sodium phosphate, dibasic (49 mg / 100 mL) + Alanine (422 mg / 100 mL) + Arginine (432 mg / 100 mL) + Aspartic acid (298 mg / 100 mL) + Dextrose, unspecified form (10 g / 100 mL) + Glutamic acid (314 mg / 100 mL) + Glycine (212 mg / 100 mL) + Histidine (128 mg / 100 mL) + Isoleucine (280 mg / 100 mL) + Leucine (425 mg / 100 mL) + Lysine acetate (446 mg / 100 mL) + Magnesium chloride (30 mg / 100 mL) + Methionine (73 mg / 100 mL) + N-acetyltyrosine (115 mg / 100 mL) + Phenylalanine (126 mg / 100 mL) + Potassium chloride (97 mg / 100 mL) + Proline (307 mg / 100 mL) + Serine (225 mg / 100 mL) + Sodium chloride (120 mg / 100 mL) + Threonine (170 mg / 100 mL) + Tryptophan (85 mg / 100 mL) + Valine (212 mg / 100 mL) Solution Intravenous Hospira Healthcare Ulc 1987-12-31 2012-08-03 Canada Aminosyn II and Dextrose Sodium phosphate, dibasic (49.3 mg/100mL) + Alanine (422 mg/100mL) + Arginine (432 mg/100mL) + Aspartic acid (298 mg/100mL) + D-glucose monohydrate (10 g/100mL) + Glutamic acid (314 mg/100mL) + Glycine (212 mg/100mL) + Histidine (128 mg/100mL) + Isoleucine (280 mg/100mL) + Leucine (425 mg/100mL) + Lysine acetate (446 mg/100mL) + Magnesium chloride hexahydrate (30 mg/100mL) + Methionine (73 mg/100mL) + N-acetyltyrosine (115 mg/100mL) + Phenylalanine (126 mg/100mL) + Potassium chloride (97 mg/100mL) + Proline (307 mg/100mL) + Serine (225 mg/100mL) + Sodium chloride (120 mg/100mL) + Threonine (170 mg/100mL) + Tryptophan (85 mg/100mL) + Valine (212 mg/100mL) Injection, solution Intravenous Hospira, Inc. 1988-11-01 2010-01-01 US 
Amo Endosol Extra Sodium phosphate, dibasic (0.42 mg / mL) + Calcium chloride (0.154 mg / mL) + Dextrose, unspecified form (0.92 mg / mL) + Glutathione disulfide (0.184 mg / mL) + Magnesium chloride (0.2 mg / mL) + Potassium chloride (0.38 mg / mL) + Sodium bicarbonate (2.1 mg / mL) + Sodium chloride (7.14 mg / mL) Powder, for solution Intraocular Amo Canada Company 1993-12-31 2008-07-30 Canada Biphozyl Hämodialyse-/Hämofiltrationslösung Sodium phosphate, dibasic dihydrate (0.187 g/L) + Magnesium chloride hexahydrate (3.05 g/L) + Potassium chloride (0.314 g/L) + Sodium bicarbonate (2.12 g/L) + Sodium chloride (7.01 g/L) Solution Hemodialysis; Intravenous Baxter Holding B.V. 2015-05-27 Not applicable Austria 
BIPHOZYL SOLUTION FOR HAEMODIALYSIS / HAEMOFILTRATION Sodium phosphate, dibasic dihydrate (0.187 g/L) + Magnesium chloride hexahydrate (3.05 g/L) + Potassium chloride (0.314 g/L) + Sodium bicarbonate (2.122 g/L) + Sodium chloride (7.013 g/L) Solution Hemodialysis; Intravenous BAXTER HEALTHCARE (ASIA) PTE LTD 2018-07-20 Not applicable Singapore Bss Plus Sodium phosphate, dibasic (0.042 %) + Calcium chloride (0.0154 %) + Dextrose, unspecified form (0.092 %) + Glutathione disulfide (0.0184 %) + Magnesium chloride (0.02 %) + Potassium chloride (0.038 %) + Sodium bicarbonate (0.21 %) + Sodium chloride (0.714 %) Kit; Solution Intraocular Alcon, Inc. 1982-12-31 Not applicable Canada - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image B.T.ENEMA 210 ML LAVMAN Sodium phosphate, dibasic (3.5 g/59ml) + Sodium phosphate, monobasic (9.5 g/59ml) Enema Rectal YENİŞEHİR LABORATUARI LTD. ŞTİ. 2020-08-14 2022-04-11 Turkey 
B.T.ENEMA 67,5 ML LAVMAN Sodium phosphate, dibasic (3.5 g/59ml) + Sodium phosphate, monobasic (9.5 g/59ml) Enema Rectal YENİŞEHİR LABORATUARI LTD. ŞTİ. 2020-08-14 2022-04-11 Turkey Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral Rising Pharmaceuticals, Inc. 2012-06-28 Not applicable US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral KAISER FOUNDATION HOSPITALS 2014-07-07 2018-01-31 US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral Carilion Materials Management 2012-06-28 Not applicable US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral Cardinal Health 2012-06-28 2018-03-31 US 
Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral American Health Packaging 2014-05-13 2020-06-30 US Dibasic Sodium Phosphate, Monobasic Potassium Phosphate and Monobasic Sodium Phosphate Sodium phosphate, dibasic (852 mg/1) + Monopotassium phosphate (155 mg/1) + Sodium phosphate, monobasic, monohydrate (130 mg/1) Tablet Oral Avera McKennan Hospital 2015-03-11 2017-05-24 US 
ISOLYTE SISE 1000 ML(SETLI) Sodium phosphate, dibasic, heptahydrate (0.012 %) + Sodium gluconate (0.5 %) + Magnesium chloride (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey ISOLYTE SISE 1000 ML(SETSIZ) Sodium phosphate, dibasic, heptahydrate (0.012 %) + Sodium gluconate (0.5 %) + Magnesium chloride (0.03 %) + Monopotassium phosphate (0.00082 %) + Potassium chloride (0.037 %) + Sodium acetate trihydrate (0.37 %) + Sodium chloride (0.53 %) Solution Intravenous ECZACIBAŞI-BAXTER HASTANE ÜRÜNLERİ SAN.VE TİC. A.Ş. 2020-08-14 Not applicable Turkey
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as alkali metal phosphates. These are inorganic compounds in which the largest oxoanion is phosphate, and in which the heaviest atom not in an oxoanion is an alkali metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Alkali metal oxoanionic compounds
- Sub Class
- Alkali metal phosphates
- Direct Parent
- Alkali metal phosphates
- Alternative Parents
- Inorganic sodium salts / Inorganic oxides
- Substituents
- Alkali metal phosphate / Inorganic oxide / Inorganic salt / Inorganic sodium salt
- Molecular Framework
- Not Available
- External Descriptors
- sodium phosphate (CHEBI:34683)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 22ADO53M6F
- CAS number
- 7558-79-4
- InChI Key
- BNIILDVGGAEEIG-UHFFFAOYSA-L
- InChI
- InChI=1S/2Na.H3O4P/c;;1-5(2,3)4/h;;(H3,1,2,3,4)/q2*+1;/p-2
- IUPAC Name
- disodium hydrogen phosphate
- SMILES
- [Na+].[Na+].OP([O-])([O-])=O
References
- General References
- Rex DK: Dosing considerations in the use of sodium phosphate bowel preparations for colonoscopy. Ann Pharmacother. 2007 Sep;41(9):1466-75. Epub 2007 Jul 24. [Article]
- Schanz S, Kruis W, Mickisch O, Kuppers B, Berg P, Frick B, Heiland G, Huppe D, Schenck B, Horstkotte H, Winkler A: Bowel Preparation for Colonoscopy with Sodium Phosphate Solution versus Polyethylene Glycol-Based Lavage: A Multicenter Trial. Diagn Ther Endosc. 2008;2008:713521. doi: 10.1155/2008/713521. [Article]
- Ehrenpreis ED: Increased serum phosphate levels and calcium fluxes are seen in smaller individuals after a single dose of sodium phosphate colon cleansing solution: a pharmacokinetic analysis. Aliment Pharmacol Ther. 2009 Jun 1;29(11):1202-11. doi: 10.1111/j.1365-2036.2009.03987.x. Epub 2009 Feb 27. [Article]
- Razzaque MS: Phosphate toxicity: new insights into an old problem. Clin Sci (Lond). 2011 Feb;120(3):91-7. doi: 10.1042/CS20100377. [Article]
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- FDA Guide: Sodium Phosphate Tablet [Link]
- ChemIDPlus: Sodium Phosphate [Link]
- External Links
- KEGG Compound
- C13558
- ChemSpider
- 22625
- ChEBI
- 34683
- ChEMBL
- CHEMBL1060
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Colon Cleansing 1 4 Completed Treatment Obstructive Sleep Apnea (OSA) / Psoriasis (PsO) 1 4 Recruiting Treatment Colorectal Neoplasms / Surgery 1 4 Unknown Status Treatment Critical Care 1 3 Completed Not Available Colonoscopy 1 3 Completed Treatment Bowel preparation therapy 1 3 Completed Treatment Cataracts 2 2 Completed Prevention Cataracts / Ocular Inflammation 1 2 Completed Treatment Acute Lymphoblastic Leukaemias (ALL) 1 2 Not Yet Recruiting Treatment Nasopharyngeal Neoplasms 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Solution Intravenous 10.50 g/1000ml Injection, solution Intravenous Powder, for solution Intraocular Solution Hemodialysis; Intravenous Solution Hemodialysis; Intravenous 0.187 g/L Solution Intravenous Kit; solution Intraocular Solution, concentrate Rectal Solution Rectal Liquid Oral Kit Intravenous Solution Unknown Tablet, coated Oral Liquid Buccal Spray Buccal Kit; solution Intraocular; Irrigation Liquid Topical Tablet, effervescent Oral Emulsion Intravenous Emulsion Parenteral Tablet Oral Solution Oral Solution Oral 1.2 g/5ml Solution Hemodialysis Injection Intravenous Enema Rectal Solution Respiratory (inhalation) Injection, solution, concentrate Intravenous Powder Oral Solution Oral 0.9 g/5ml Irrigant Irrigation Solution Irrigation Liquid Irrigation Syrup Solution - Prices
- Not Available
- Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region US7687075 No 2010-03-30 2028-06-22 US
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -1 Chemaxon pKa (Strongest Acidic) 1.8 Chemaxon Physiological Charge -2 Chemaxon Hydrogen Acceptor Count 4 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 83.42 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 12.41 m3·mol-1 Chemaxon Polarizability 5.24 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
Transporters
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Not Available
- Specific Function
- Not Available
- Gene Name
- SLC20A1
- Uniprot ID
- Q8WUM9
- Uniprot Name
- Sodium-dependent phosphate transporter 1
- Molecular Weight
- 73699.01 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Virus receptor activity
- Specific Function
- Sodium-phosphate symporter which seems to play a fundamental housekeeping role in phosphate transport by absorbing phosphate from interstitial fluid for normal cellular functions such as cellular m...
- Gene Name
- SLC20A2
- Uniprot ID
- Q08357
- Uniprot Name
- Sodium-dependent phosphate transporter 2
- Molecular Weight
- 70391.755 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- Involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 70-80% of the apical influx.
- Gene Name
- SLC34A1
- Uniprot ID
- Q06495
- Uniprot Name
- Sodium-dependent phosphate transport protein 2A
- Molecular Weight
- 68936.53 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport. It may be the main phosphate transport protein in the intestinal brush border membrane. May have a role in the s...
- Gene Name
- SLC34A2
- Uniprot ID
- O95436
- Uniprot Name
- Sodium-dependent phosphate transport protein 2B
- Molecular Weight
- 75758.535 Da
References
- Biber J, Hernando N, Forster I: Phosphate transporters and their function. Annu Rev Physiol. 2013;75:535-50. doi: 10.1146/annurev-physiol-030212-183748. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- No
- General Function
- Sodium:phosphate symporter activity
- Specific Function
- May be involved in actively transporting phosphate into cells via Na(+) cotransport in the renal brush border membrane. Probably mediates 20-30% of the apical influx.
- Gene Name
- SLC34A3
- Uniprot ID
- Q8N130
- Uniprot Name
- Sodium-dependent phosphate transport protein 2C
- Molecular Weight
- 63548.94 Da
References
- Kirchheiner J, Meineke I, Muller G, Roots I, Brockmoller J: Contributions of CYP2D6, CYP2C9 and CYP2C19 to the biotransformation of E- and Z-doxepin in healthy volunteers. Pharmacogenetics. 2002 Oct;12(7):571-80. [Article]
Drug created at July 11, 2018 17:31 / Updated at January 08, 2021 01:07